Skip to main content
OpenTrials
Completed

NCT Number: NCT01214863

AcrySof Toric Clinical Results

This study is an evaluation of visual outcomes of subjects implanted with the AcrySof Toric Intraocular Lenses (IOLs) Models SN60T3, SN60T4, and SN60T5.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Alcon Call Center for Trial Locations

Fort Worth, Texas, 76134, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed with cataracts; has astigmatism falling in range of AcrySof Toric lens as assessed by the AcrySof Toric calculator

Exclusion criteria

  • Ocular comorbidities affecting visual outcome data,
  • Prior refractive surgery,
  • Irregular astigmatism

Treatment and study plan

T3

Device

Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T3

T4

Device

Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T4

T5

Device

Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T5

Primary outcomes

  1. Visual Acuity

    Time frame: 1 day to 6 months

Secondary outcomes

  1. Postoperative refractive cylinder

    Time frame: 1day to 6 months

Sponsors and collaborators

Lead sponsor

Alcon Research

Industry

Registry information

Official study title

Clinical Results With the AcrySof Toric Intraocular Lens (IOL)

Important dates

Study start
2007
Primary completion
2008
First posted
Oct 5, 2010
Registry last updated
Oct 1, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.